pSivida Corp (PSDV) Announces ILUVIEN® Receives Marketing Authorization In Italy For Treatment Of Chronic Diabetic Macular Edema
6/23/2014 9:00:34 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by